2018 New Drug Update

Consult Pharm. 2018 Apr 1;33(4):188-198. doi: 10.4140/TCP.n.2018.188.

Abstract

Five new drugs marketed within the last year, which are used for medical problems often experienced by the elderly, have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include an anticoagulant, an antiparkinson agent, an agent for tardive dyskinesia, an agent for psoriasis, and an agent for constipation. The drugs reviewed are betrixaban, safinamide mesylate, valbenazine tosylate, guselkumab, and plecanatide.

MeSH terms

  • Aged
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants / therapeutic use
  • Antiparkinson Agents / therapeutic use
  • Benzamides / therapeutic use
  • Benzylamines / therapeutic use
  • Constipation / drug therapy
  • Drug Approval*
  • Humans
  • Natriuretic Peptides / therapeutic use
  • Psoriasis / drug therapy
  • Pyridines / therapeutic use
  • Tardive Dyskinesia / drug therapy
  • Tetrabenazine / analogs & derivatives
  • Tetrabenazine / therapeutic use
  • Valine / analogs & derivatives
  • Valine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antiparkinson Agents
  • Benzamides
  • Benzylamines
  • Natriuretic Peptides
  • Pyridines
  • guselkumab
  • valbenazine
  • betrixaban
  • plecanatide
  • safinamide
  • Valine
  • Alanine
  • Tetrabenazine